Study #2023-0224
A Phase 2a, double-blind, placebo-controlled, multi-center, randomized study evaluating LSTA1 when added to standard of care (SoC) versus standard of care alone in subjects with advanced solid tumors (BOLSTER)
MD Anderson Study Status
Enrolling
Treatment Agent
LSTA1, Durvalumab, Cisplatin, Gemcitabine, FOLFOX regimen, Placebo
Description
The goal of this clinical trial is to test a new drug plus standard treatment compared with standard treatment alone in patients with previously untreated cholangiocarcinoma or those that have progressed after first-line treatment for cholangiocarcinoma. The main questions it aims to answer are: * is the new drug plus standard treatment safe and tolerable * is the new drug plus standard treatment more effective than standard treatment
Resources and Links
Phone Number: 1-877-MDA-6789
Information and next steps
Disease:
Cholangiocarcinoma, Gallbladder Cancer, Gallbladder Carcinoma, Intrahepatic Cholangiocarcinoma, Extrahepatic Cholangiocarcinoma, Bile Duct Cancer, Gall Bladder Cancer, Gall Bladder Carcinoma
Study phase:
Phase II
Physician name:
Ian Hu
Department:
Gastrointestinal Medical Oncology
For general questions about clinical trials:
1-855-478-0144
Help #EndCancer
Give Now
Donate Blood
Our patients depend on blood and platelet donations.
Shop MD Anderson
Show your support for our mission through branded merchandise.